Immune system modulation via intentional allo-rejection

Immune system modulation via intentional allo-rejection" is not a specific molecule or receptor but rather describes a **therapeutic strategy or immunological process**. The term refers to the deliberate manipulation of the immune system to induce or control allogeneic (allo-) rejection—an immune response against non-self antigens from members of the same species, such as in organ transplantation[2][4][6]. Allo-rejection is mediated by recognition of donor antigens (primarily major histocompatibility complex [MHC] molecules and minor histocompatibility antigens) by recipient T cells and other components of both innate and adaptive immunity[2][3][4][5]. This process involves several molecular pathways—including direct, indirect, and semi-direct allorecognition—whereby recipient antigen-presenting cells (APCs) present donor-derived peptides to T lymphocytes[4][5][6]. Key cellular players include CD8+ cytotoxic T cells, CD4+ helper T cells, B cells producing alloantibodies, natural killer (NK) cells recognizing missing self-MHC or foreign MHC molecules, monocytes/macrophages responding to "danger" signals and complement activation products[3][5]. Therapeutically modulating this process can involve blocking costimulatory signals (e.g., CD40-CD40L interaction), cytokine signaling pathways like IL-6/IL-6R that drive inflammation and graft injury[1], or engineering donor tissues/cells to evade detection by host immunity through expression of inhibitory ligands such as HLA-E/G or CD47 ("don't eat me" signal)[8]. Because "Immune system modulation via intentional allo-rejection" does not refer to a single defined molecular target but rather an immunological phenomenon involving multiple receptors/molecules/pathways across both innate and adaptive immunity[2][3], it cannot be classified as a canonical therapeutic target like an enzyme or receptor. Therefore: > This entry is **not a valid molecular target**; it represents an immunological strategy/process involving many targets. If you are seeking structured information for specific molecules involved in this process—such as MHC class I/II molecules, IL-6 receptor, CD40/CD40L axis—you should specify those individual targets for accurate data extraction.

Other names

Alloimmune response modulationAllorecognition pathway targetingAllograft rejection modulationTransplant rejection immune modulation